Glucocorticoids (GC) modulate immune function in a number of ways, including suppression of T cell proliferation and other IL-2-mediated T cell functions. These inhibitory effects are similar to those induced by transforming growth factor-,il (TGF-,61), a cytokine with potent T cell inhibiting activities.
Introduction
Glucocorticoids (GC)1 are immunosuppressive and can induce lympholysis in vitro and in vivo. Although these properties have resulted in the wide clinical application of GC as antiinflammatory and antineoplastic agents, the mechanisms by which they modulate immune system function are unclear. One possibility, supported by accumulating experimental evidence, is that GC inhibit the synthesis and release of immunoregulatory molecules, such as IL-2 and y-IFN, by activated T cells (1) (2) (3) (4) (5) . These lymphokines promote the expansion ofantigen-specific helper/inducer or cytotoxic/suppressor T cell clones as well as natural killer cells that are involved in immune regulation and surveillance (6) . The steady-state mRNA levels ofboth IL-2 and y-IFN are significantly decreased when T cells are activated in vitro with purified phytohemagglutinin (PHAp) and phorbol myristate acetate (PMA) in the presence of dexamethasone (4) . The inhibitory effects of GC on immunoregulatory T cell functions in vivo was demonstrated in studies that showed inhibition of both IL-2 and IL-2 receptor (IL-2R) gene expression in activated T cells from GC-treated patients with pulmonary sarcoidosis (7, 8) . Recently, it has been shown that transforming growth factor-,Bl (TGF-#31) (9) , a cytokine produced by mitogen-activated T cells, B cells, monocytes, and fibroblasts, is a potent inhibitor of multiple T cell functions in vitro (10) (11) (12) (13) (14) (15) (16) (17) . In common with the other members of the TGFB gene family, TGF-3l1 has profound stimulatory effects on fibroblast chemotaxis and on expression ofthe genes for the extracellular matrix proteins collagen and fibronectin (18) . Furthermore, it has been shown that TGF-,B1 can upregulate its own production by these cells (19) . Although several target genes regulated by TGF-,B1 have been identified in a variety of human cells and cell lines, little is known about the mechanisms that regulate the expression of the TGF-j31 gene.
The immunosuppressive effects of GC and TGF-tl on T lymphocytes share important similarities. Both inhibit IL-2mediated T cell functions, such as lectinand IL-2-induced T cell proliferation and generation of regulatory T cells in vitro (20) (21) (22) and in vivo (23, 24) . For this reason, we investigated whether GC altered the TGF-,B1 gene expression in mitogenactivated human T cells. Our results show that dexamethasone significantly increases the expression of the TGF-,B1 gene and its protein product in these cells. Its effect on the TGF-j31 gene is observed as early as 1 h after T cell induction with PHA-p/ PMA. The enhancement of the steady-state TGF-tll mRNA levels in response to cycloheximide and the results of in vitro nuclear transcription studies indicate that dexamethasone may regulate TGF-, I gene expression at a transcriptional level. Methods Cells. PBMC, 2 x 108-2.5 x I09 were isolated by density gradient separation from buffy coat by-products of whole blood donated by healthy volunteers (Interstate Blood Bank, Philadelphia, PA). Buffy coats from 20 different donors, 21-31 yr old, were studied. Adherent cell-depleted T cells were prepared by incubating the PBMC in plastic petri dishes for 4 h and passing the nonadherent cells twice over nylon wool columns (25) . Purity of nylon wool nonadherent T cell populations was determined by flow cytometry and histocytochemistry, using an FITC-conjugated anti-pan T cell MAb anti-CD2 (Becton Dickin-son Immunocytometry Systems, Mountain View, CA), and a phycoerythrin-conjugated MAb anti-CD14 (Becton Dickinson) which reacts with cells ofmonocytic origin. Flow cytometric determination ofmembrane immunofluorescence with two color analysis (26) showed that T cells were > 98% CD2+ and < 1% CD14+ when compared with nonbinding FITCand phycoerythrin-labeled MAbs; < 1% cells reacted with alpha-naphthyl-acetate esterase. Viability was > 99% as assessed by trypan blue dye exclusion.
Activation of T cells and culture conditions. CD2+ lymphocytes were cultured at 2 X 106/ml in RPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 5% defined pooled human AB serum (Gibco), penicillin 100 U/ml, streptomycin (100 Mg/ml) in 25-cm2 tissue culture flasks (Coming Glass Works, Coming, NY) in a humidified 5% CO2 incubator at 370C. T cells were stimulated with 2 jtg/ml PHAp (Wellcome Diagnostics, Research Triangle Park, NC) and 30 ng/ml PMA (Sigma Chemical Co., St. Louis, MO) at 370C for 1-72 h. In some experiments, the human AB serum was omitted from cultures that were harvested at I h. Dexamethasone (ESI Pharmaceuticals, Cherry Hill, NJ) (100 g/ml-200 ug/ml) was added to T cell cultures as indicated, the incubations were stopped at appropriate serial time points, and cells were harvested for RNA extraction. In some experiments 30 ng/ml cycloheximide (Sigma), was added to cultures at the times indicated. To quantitate TGF-(lI levels, supernatants were obtained from T cells cultured in serum-free Aim V medium (Gibco) in the presence or absence of PHA-p (2 ,g/ml)/PMA (30 ng/ml) with or without dexamethasone (20-100 jug/ml), for 96 h. Supernatants were brought to 1 M final concentration with acetic acid, and were incubated for 10 min-2 h at room temperature to activate latent TGF-,B1. Samples were neutralized to pH 7.0-7.4, Iyophilized to dryness, and resuspended in 100 1l of 0.1% BSA (Sigma) in Dulbecco's modified Eagle's medium (Gibco).
RNA isolation and Northern hybridizations. Total RNA was isolated from cells using guanidinium isothiocyanate, according to the method ofChirgwin et al. (27) . RNA content ofindividual samples was equalized by ethidium bromide staining of previously run 1% nondenaturing agarose gels. The samples containing equal amounts of RNA were then separated on 1% agarose-formaldehyde gels and transferred to Hybond-N nylon membranes (Amersham Corp., Arlington Heights, IL). Nick translated, [a-32P] dCTP-labeled cDNA was hybridized to the filters in 50% formamide, 0.1% SDS, lx Denhardt's solution, 2X standard saline citrate (SSC; I x SSC is 0. 15 M NaCl and 0.0 15 M sodium citrate), 50 ng/ml salmon sperm DNA, with a sp act of 3-4 x 101 cpm/,ug, at 42°C for 16-20 h. After hybridization, filters were washed twice for 5 min at 22°C in I x SSC-0. 1% SDS, then twice for 30 min at 55°C in 0.1X SSC-0.1% SDS. Autoradiography was performed by exposing to XAR film (Eastman Kodak Co., Rochester, NY) at -70°C. Quantitation ofthe radioactive band intensities in autoradiographs was performed by scanning laser densitometry and the areas under tracings expressed as a fold increase relative to control samples as indicated.
DNA probes. The TGF-,ll probe is a gel purified 1.05-kb cDNA insert cloned in pSB64, that hybridizes to a 2.5-kb TGF-fll mRNA (kindly donated by Dr. Richard Derynck, Genentech) (28) . Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPD) cDNA in pBR322 that hybridizes to a 1.7-kb GAPD mRNA was used as a control probe.
Nuclear transcription and isolation oflabeled RNA. Transcription was measured in a nuclear runofftranscription assay (29) . For preparation ofnuclei, 2 x 108 cells were suspended in 9 ml ofcold buffer A (0.3 M sucrose, 10 mM NaCI, 5 mM MgCl2, 10 mM Tris, pH 7.5, 0.5 mM dithiothreitol). 1 ml of 10% Triton X-100 was added, cells were homogenized with a nuclei homogenizer (Con-Torque power unit; Eberbach Corp., Ann Arbor, MI) three times at 300 rpm and the homogenate centrifuged 5 cubations were for 20 min at 250C, and incorporation of[32P]-CTP was followed by TCA precipitation of l-Ml aliquots. Transcription was terminated by addition of 900 Ml of buffer C (100 mM NaCl, 10 mM Tris-HC1 buffer at pH 7.5, 2 mM KCI, 1 mM EDTA, and 0.5% SDS). The samples were digested with 100 Mg/ml proteinase K for 60 min at 42°C after the addition of yeast tRNA (100 Mg in 10 Ml H20). Samples were extracted with phenol/chloroform, adjusted to 10% TCA and 10% saturated sodium pyrophosphate, and nucleic acids precipitated. Samples were then centrifuged for 10 min at 4°C, and pellets were washed with 70% ethanol, dried, and dissolved in 100 Ml buffer with 10 mM Tris, 1 mM EDTA, and 0.1% SDS. An additional 100Mg ofyeast tRNA was added, and nucleic acids were ethanol precipitated from 2.5 M ammonium acetate. The pellets were dissolved in 100 Ml of buffer that contained 20 mM Tris-HCl, 10 mM MgCI2, and 2 mM CaCl2, pH 7.5, and incubated for 30 min at 37°C with 100 Mg/mI RNAse-free DNAse (Promega) and 1 U/Ml RNAsin. Samples were extracted with phenol/ chloroform, and ethanol precipitated from 0.3 M sodium acetate. Labeled transcripts were resuspended in prehybridization buffer, and 5 Ml TCA were precipitated and counted. 8.5-10.5 X 106 cpm of each sample were adjusted to 400 M in the same buffer and hybridized to the filters with appropriate probes with continuous shaking at 42°C for 72 h. The filters were washed for 15 min in 2X SSC and treated with RNaseA (10 Mg/ml in 2x SSC) for 15 min at 37°C; washed in 2X SSC, 0.1%, SDS for 15 min at room temperature and for 15 min at 60°C; dried and exposed to film, then cut out and 32p content directly determined in a scintillation counter.
TGF-flJ assay. The CCL64 assay was performed as described by Tucker et al. (30) . In brief, CCL64 cell line obtained from American Type Culture Collection, Bethesda, MD, was maintained in DMEM (Gibco), supplemented with penicillin (100 U/mi), streptomycin (100 Mg/ml), and 10% defined fetal calf serum (Gibco) in a humidified 5% CO2 incubator at 37°C. To assay for TGF-#1, 6 X I04 cells/well were grown in 24-well tissue culture plates (3548; Costar Corp., Cambridge, MA) until nearly confluent when media was changed to DMEM 5% FCS. After 24 h, 300 M1 of each supernatant was added to triplicate wells. Unless otherwise stated, each supernatant was tested in dilutions of 1:10, 1:100, 1:1,000, and 1:10,000. After 24 h incubation, the cells were pulsed with [3H] thymidine (2 MCi/ml) for 4 h, the medium was removed, and the cell layers were washed with 1 ml of ice cold 10% TCA for 10 min. Cells were solubilized in 250 Ml of 0.25 N NaOH for 10 min and harvested using a microculture harvesting device and counted in liquid scintillation counter to measure [3H] thymidine uptake. For each assay a standard curve was obtained with 4 ng-l pg/ml of a purified human TGF-#1 standard (Rand D Systems, Inc., Minneapolis, MN). Results were expressed as counts per minute. To neutralize TGF-,B1 activity, a rabbit anti-TGF-61 (AB-IO-NA, R and D Systems) was added at 1:500 and 1:1,000 dilutions.
Immunoblot analysis for TGF-,81. Equal volume aliquots of the supernatants were slot-blotted on nitrocellulose membranes, using a slot-blot apparatus (Bio-Dot SF; Bio-Rad Laboratories, Richmond, CA) according to manufacturer's instructions. Membranes were then reacted with a rabbit polyclonal antibody to TGF-i1, (AB-20-PB, R and D Systems) and the bound antibody visualized with horseradish peroxidase-coupled goat anti-rabbit IgG.
Results

Stimulation of TGF-#J gene expression in activated Tcells. To determine the expression of the TGF-#lI gene by T cells, other
Glucocorticoid Regulation ofTransforming Growth Factor-#J Expression 1575 mononuclear cells that produce TGF-,l were removed. Since T cells cannot be induced to produce IL-2, to express high affinity IL-2 receptors, or to proliferate by PHA-p alone in the absence of adherent cells (6, 30, 31) , PMA was also added to T cell cultures. The phorbol ester is the most effective substitute for adherent cells in activating adherent cell-depleted T cells with mitogen. To confirm the expression of TGF-#lI gene by human T cells, adherent cell depleted-T cells were cultured with or without PHA-p/PMA for 24 h. Total RNA from these cells was isolated and examined by Northern hybridization with the TGF-Il cDNA. To determine the baseline TGF-#lI mRNA levels, T cells were subjected to RNA extraction immediately after they were isolated from the nylon wool columns. without dexamethasone (P < 0.01) (Fig. 2 a) . Dexamethasone induced a concentration-dependent increase in steady-state levels mRNA in PHA-p/PMA treated T cells, as well ( Fig. 3) . In 15 donors, the increase in TGF-#l mRNA levels in PHA-p/ PMA stimulated T cells after 24 h ofincubation with 100 ,ug/ml and 200 gg/ml dexamethasone was 3.2±0.5 (2 SD)and 6.2±0.4 (2 SD)-fold respectively. As shown in Fig. 4 , the stimulatory effect ofdexamethasone was detected as early as 1 h after it was added to T cells. TGF-,lB mRNA levels were two and fourfold greater in to those that did not receive dexamethasone. Similar results were obtained in experiments with T cells from four additional individuals. The dexamethasone-induced increase in TGF-#lI mRNA levels reached a peak at 4-6 h and persisted for at least 24 h, as long as dexamethasone and the mitogens were present in the culture medium (data not shown). We next investigated whether the presence of dexamethasone at the initiation of T cell activation was necessary for its stimulatory effect on TGF-fli mRNA levels. As illustrated in Fig. 5 , when dexamethasone (100 ug/ml) was added as late as 12 h after T cell stimulation by PHA-p/PMA it caused a twofold increase in TGF-#3l mRNA levels over the subsequent 12 h (Fig. 5, a and b) . In contrast, when dexamethasone was added to cultures 20 h after PHA-sp/PMA, it was ineffective in elevating TGF-3l mRNA levels in T cells ( Fig. 5 c) . Similar results were obtained in experiments with T cells from seven additional individuals.
Effect of cycloheximide on dexamethasone-stimulated expression of TGF-f3 gene by activated T cells. We next investigated whether dexamethasone-induced stimulation ofTGF-#lI mRNA expression by PHA-p/PMA activated T cells required de novo protein synthesis. In experiments not shown, we found that 30 ,g/ml cycloheximide caused > 97% inhibition of 14Cleucine incorporation into newly synthesized protein in PHAp/PMA-activated T cells. Therefore, nonactivated T cells and T cells activated with PHA-p/PMA in the presence or absence of dexamethasone (100 ,g/ml) were cultured with cycloheximide (30 ,g/ml) for 6 h. As shown in Fig. 6, unstimulated (Fig.   6 , a and b), as well as PHA-p/PMA-activated T cells cultured in the absence (Fig. 6 , c and d) or in the presence (Fig. 6 , e andj) of dexamethasone showed increased steady-state TGF-,l mRNA levels after incubation with cycloheximide for 6 h. In contrast, the steady-state mRNA levels for GAPD, used as a control, did not change. Similar results were obtained in experiments with T cells from five additional normal donors. transcription assays were performed with nuclei isolated from T cells that had been incubated for 6 h with PHA-p/PMA in the presence or absence ofdexamethasone (100 ,g/ml). The results of three experiments summarized in Fig. 7 , show that the rate of transcription of the TGF-,B1 gene is increased over twofold by 100 ,g/ml dexamethasone, while stimulation with mitogen did not affect the transcription rate. However, addition ofdexamethasone to cells incubated with mitogens, resulted in an increase in the T cell TGF-,B1 gene transcription rate beyond that seen with dexamethasone alone. These observations suggested that dexamethasone and mitogens stimulate TGF-j31 mRNA expression by different mechanisms.
Effect of dexamethasone on production of TGF-01 by T cells. To ascertain whether the dexamethasone-induced increase in steady-state TGF-,BI mRNA levels is accompanied by a concomitant increase in the production of TGF-l protein, we determined the biological activity of TGF-#I in T cell supernatants. For this purpose, T cells were cultured without serum in the presence or absence ofPHA-p/PMA with or without dexamethasone. The collected supernatants were assayed for TGF-#31 biologic activity in the CCL64 bioassay which uses a lung epithelial cell line (MV1 Lu) that is known to be growth inhibited by TGF-# 1 (26) . As seen in Table I , whereas supernatants from unactivated T cells inhibited proliferation ofCCL64 cells by 27%, supernatants from activated T cells resulted in a 62% inhibition. Although the levels of TGF-,B1 produced by T cells showed a large variation, acidified supernatants conditioned by unactivated T cells had -8 pg/ml TGF-,Bl-like biologic activity; supernatants from PHA-activated T cells had twofold higher levels of -16 pg/ml dexamethasone treatedactivated T cells had the highest levels of -30 pg/ml. We realize the shortcomings of this biological assay and are in the process ofsetting up a more direct and sensitive ELISA assay to confirm our present observations. The supernatants from T cells that were activated in the presence of dexamethasone induced a further inhibition to 82%. To confirm that the inhibition of CCL64 proliferation was indeed due to TGF-fl1, the supernatants were treated with a specific anti-TGF-,3l antibody. The antibody significantly reduced the inhibitory effects of supernatants from T cells activated in the presence of dexa- methasone indicating that these samples contained TGF-f3l activity which was blocked by the addition of an anti-TGF-,Bl antibody (Table I) . Although the majority of TGF-(#1 activity was obtained after acidification of supernatants, unacidified supernatants also contained TGF-,31 activity, although to a lesser extent compared to acid-activated samples, i.e., 69% vs. 82% after acidification. Whether the majority of dexamethasone-induced TGF-#31 is in latent form will be tested by experiments in which we shall compare antibody neutralization of acidified versus nonacidified supernatants. The presence of TGF-, I in supernatants ofactivated peripheral blood lymphocytes and T cells was further demonstrated by immunoblot analysis. A representative example from four experiments is seen in Fig. 8 and shows that both peripheral blood lymphocytes and T cells produce immuno-detectable TGF-j31 that appears to be highest in concentration in dexamethasone-treated T cell supernatants.
Discussion
In this study we examined the regulation of TGF-#lI gene expression by dexamethasone in normal human T cells activated by PHA-p and PMA. The results show that dexamethasone significantly enhances the expression of the TGF-,B1 gene and the production of the corresponding protein by activated T 1578 0. AyanlarBatuman, A. P. Ferrero, A. Diaz, and S. A. Jimenez D +D Figure 8 . Dexamethasone-mediated stimulation of TGF-f,1 production by activated lymphocytes. Immunoblot analysis was performed with supernatants from pHA-p/PMA-treated PBL and T cells of one individual, that were cultured with or without dexamethasone (100 ,ug/ml), and were visualized with a rabbit anti-TGFB-l antibody as described in Methods. cells in a dose and time dependent fashion. Although the biological significance of this finding is unknown, the increased synthesis of an immunosuppressor cytokine could be one mechanism by which GC mediate immunosuppression. Since TGF-,B1 is a potent inhibitor of T cell proliferation, its increased synthesis by activated T cells could be a biologic mechanism by which T cells limit the extent of their proliferative response to antigenic stimulation. Stimulation and subsequent activation ofT cells by specific antigens or by mitogens requires two signals: (a) the occupation ofthe T cell antigen receptor, an effect which can be mimicked by PHA-p; and (b) an effect of accessory cells, mimicked by agents that activate protein kinase C, such as phorbol esters (6, 31, 32) . In response, multiple T cell genes are sequentially activated, over a period of several days (33) , resulting in blastogenesis within 12 h, cell division by 24-48 h, with subsequent differentiation into immunocompetent T cells. Our time course experiments demonstrate that dexamethasone exercises its effect on TGF-f,1 gene expression only during the first 12 h after activation, a time period corresponding to the blast transformation stage of T cell activation. Dexamethasone has other effects as well. For example, dexamethasone is known to inhibit gene expression of IL-2 and y-IFN, both of which are expressed during the initial 2 h of T cell activation with PHA-p and PMA (4) . We have reported that dexamethasone significantly decreases cell surface expression ofthe high affinity IL-2 receptor (IL-2R) in PHA-p/PMA activated T cells in a similar time frame (34) , suggesting that during the initial 12 h ofT cell induction, expression of several genes important in the regulation of T cell activation can be modulated by dexamethasone. More recently it was found that TGF-,B1 can inhibit the progression of activated T cells from the G1 to the S phase of the cell cycle and can inhibit IL-2R generation in murine T cell lines (35) . Taken together, these observations raise the possibility that inhibition of T cell proliferation and IL-2R generation in vivo may be mediated or potentiated by TGF-,lB, and thus, that TGF-# 1 may play a pivotal role in some human diseases. However, although TGF-# 1 can regulate expression ofthe IL-2 receptor in T cell lines, whether it alters IL-2 gene expression in human T cells is not clear (36) . Thus, it is unlikely that TGF-1 I alone is responsible for the inhibitory effects of GC on T cell functions. Physiologic variations of plasma GC levels make it difficult to assess the role of endogenous GC in modulating TGF-#l1 expression. It would be interesting to compare TGF-,B1 expression by T cells during periods of normal and elevated plasma GC levels, such as during stress when IL-2R expression and T cell activation are both decreased (37, 38) .
The superinduction of TGF-fl1 mRNA caused by cycloheximide suggests that de novo protein synthesis is required for TGF-fll mRNA degradation in T cells (39) . Whether dexamethasone inhibits a short half-lived ribonuclease(s) that degrades TGF-# I mRNA or it acts by a posttranslational mechanism that is coupled to TGFfB-mRNA degradation is not known. Since cycloheximide would inhibit new TGF-#l synthesis by PHA-p/PMA-stimulated T cells, upregulation of its mRNA by the cytokine itselfcannot account for the cycloheximide-induced increase in steady state mRNA levels for TGF-(1l.
Promoters that contain positive and negative regulatory regions, upstream and downstream of the transcriptional start site of the TGF-f31 gene, have been identified in humans (40, 41) . The positive regulatory regions of the upstream promoter for TGF-fll contain binding sites for known transcription factors including NF-1, SPI, and APl that could mediate transcriptional regulation by GC. Corticosteroid-receptor complexes are known to regulate the expression ofa variety ofgenes by stimulating the activity oftranscription factor binding sites, including NF-1, SP1, as well as AP-l either by direct binding or indirectly, by cooperation with other binding factors (42) . The in vitro nuclear transcription assays described here indicate that the increase in TGF-# I gene expression induced by dexamethasone occurs mostly at a transcriptional level whereas stimulation by mitogens appears to occur at least in part posttranscriptionally. This is not surprising since it is known that TGF-#l steady-state mRNA levels can be modulated through multiple pathways. Regulation ofthe TGF-#3I gene is posttranscriptional in certain glioblastoma and neuroblastoma cell lines (22) , and transcriptional in fibroblast cell lines in which TGF-#31 induces its own gene activation (19) , and is translational in an osteoblast-like cell line in response to fibroblast growth factor (43) .
Both TGF-# I and GC affect the functions ofa wide variety of cells. Whether the dexamethasone effect on TGF-#31 expression might be found in B cells, steroid responsive-leukemia cells, or in other hemopoietic cells, and, if so, whether this is a biologically relevant effect, remains to be answered by future studies.
